A synthetic peptide designed for research purposes only, primarily studied for its potential in appetite suppression, weight loss, and metabolic health. It’s a long-acting analogue of amylin, a hormone co-secreted with insulin that helps regulate satiety and blood sugar levels.

Cagrilintide 10MG is being actively researched for its powerful effects on weight loss, appetite regulation, and metabolic health. Studies suggest several promising benefits when used in controlled lab settings:

Suppresses hunger signals by activating amylin and calcitonin receptors in the brain.
Slows gastric emptying, helping subjects feel full longer.
Reduces caloric intake by promoting early satiety.

CAGRILINTIDE 10MG

$225.00

Combination Therapy Potential:

In trials under the name CagriSema, pairing cagrilintide with semaglutide led to greater weight loss and better glycemic control than either alone
May redefine obesity and diabetes treatment strategies in future clinical applications.

Weight Management:

Significant weight loss observed in trials—up to 10.8% body weight reduction over 26 weeks when used alone.
Enhanced results when combined with semaglutide (GLP-1 agonist), achieving up to 17.1% weight loss.
Once-weekly dosing due to long half-life (~7.3 days), improving adherence in research models.

Metabolic & Glycemic Benefits:

Improves blood sugar control by suppressing post-meal glucagon secretion.
Stabilizes glucose levels, especially in type 2 diabetes models.
Supports cardiovascular health through weight reduction and improved lipid profiles.